Loading organizations...
§ Private Profile · Suzhou, Jiangsu, China
Regend Therapeutics focuses on the human organ regenerative medicine business
Regend Therapeutics is a biotechnology company established in 2015, with its headquarters located in Suzhou, Jiangsu, China. The company focuses on the human organ regenerative medicine business, aiming to be a global leader in this specialized field. Its mission is articulated as 'Reviving Life, Reshaping Health,' reflecting its commitment to developing innovative therapeutic solutions.
As an innovative biotech company in China, Regend Therapeutics is involved in the development of treatments for conditions requiring regenerative approaches. Its portfolio includes a core product, REGEND001 cell, which is part of its efforts to address human organ regenerative medicine needs.
Regend Therapeutics has raised $5.1B across 1 funding round.
Regend Therapeutics is headquartered in Suzhou, Jiangsu, China, and operates as an innovative biotech company within China. It aims to be a global leader in human organ regenerative medicine.
Regend Therapeutics is headquartered in Suzhou, Jiangsu, China, and operates as an innovative biotech company within China. It aims to be a global leader in human organ regenerative medicine.
Regend Therapeutics has raised $5.1B across 1 funding round. Most recently, it raised $5.1B Series C in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 11, 2026 | $5.1B Series C | — | FIR Brook Capital, Gongqingcheng Fuhui, Hongtai Fund, Yuze Capital, 合肥产投, 合肥高投, 天士力资本 | Announced |
Regend Therapeutics is a biotechnology company founded in 2015, with its headquarters situated in Suzhou, Jiangsu, China. The company's primary focus is on the human organ regenerative medicine business, where it aims to establish itself as a global leader. This strategic direction positions Regend Therapeutics within a critical area of medical innovation.
The company operates with a stated mission of 'Reviving Life, Reshaping Health,' guiding its efforts in developing advanced therapeutic solutions. As an innovative biotech firm based in China, it contributes to the national and international landscape of regenerative medicine research and development.
A key aspect of Regend Therapeutics' work involves its core product, REGEND001 cell. This product is central to its approach in addressing various human organ regenerative medicine needs, reflecting the company's commitment to delivering tangible medical advancements.
Regend Therapeutics is recognized within the broader pharmaceutical and biotechnology industry. Its name has appeared in discussions concerning the pipeline for conditions such as Myelofibrosis and Idiopathic Pulmonary Fibrosis, indicating its participation or relevance in the development landscape for these complex diseases.
Operating as a private entity, Regend Therapeutics continues to pursue its objectives in regenerative medicine. Its work is concentrated on advancing its product pipeline and contributing to the therapeutic options available for organ regeneration.